Related Experiment Video
Updated: Aug 16, 2025
An Olfactory Preference Test for Measuring Olfactory Hedonic Biases in Mouse Models of Depression
Published on: July 11, 2025
QTC-4-MeOBnE Ameliorated Depressive-Like Behavior and Memory Impairment in 3xTg Mice
Mariana G Fronza1, Manoela Sacramento2, Diego Alves2
1Neurobiotechnology Research Group (GPN) - Postgraduate Program of Biotechnology, Federal University of Pelotas (UFPel), Pelotas, RS, Brazil.
Abstract:
Growing evidence has associated major depressive disorder (MDD) as a risk factor or prodromal syndrome for the occurrence of Alzheimer's disease (AD). Although this dilemma remains open, it is widely shown that a lifetime history of MDD is correlated with faster progression of AD pathology. Therefore, antidepressant drugs with neuroprotective effects could be an interesting therapeutic conception to target this issue simultaneously. In this sense, 1-(7-chloroquinolin-4-yl)-N-(4-methoxybenzyl)-5-methyl-1H-1,2,3-triazole-4- carboxamide (QTC-4-MeOBnE) was initially conceived as a multi-target ligand with affinity to β-secretase (BACE), glycogen synthase kinase 3β (GSK3β), and acetylcholinesterase but has also shown secondary effects on pathways involved in neuroinflammation and neurogenesis in preclinical models of AD. Herein, we investigated the effect of QTC-4-MeOBnE (1 mg/kg) administration for 45 days on depressive-like behavior and memory impairment in 3xTg mice, before the pathology is completely established. The treatment with QTC-4-MeOBnE prevented memory impairment and depressive-like behavior assessed by the Y-Maze task and forced swimming test. This effect was associated with the modulation of plural pathways involved in the onset and progression of AD, in cerebral structures of the cortex and hippocampus. Among them, the reduction of amyloid beta (Aβ) production mediated by changes in amyloid precursor protein metabolism and hippocampal tau phosphorylation through the inhibition of kinases. Additionally, QTC-4-MeOBnE also exerted beneficial effects on neuroinflammation and synaptic integrity. Overall, our studies suggest that QTC-4-MeOBnE has a moderate effect in a transgenic model of AD, indicating that perhaps studies regarding the neuropsychiatric effects as a neuroprotective molecule are more prone to be feasible.
Insights
A novel compound, QTC-4-MeOBnE, shows promise in preventing memory loss and depressive behaviors in Alzheimer's disease (AD) models. This neuroprotective drug targets key AD pathways, offering potential for combined treatment of major depressive disorder and AD.
Area of Science:
- Neuroscience
- Pharmacology
- Biochemistry
Background:
- Major Depressive Disorder (MDD) is linked to increased Alzheimer's Disease (AD) risk and faster pathology progression.
- Antidepressants with neuroprotective properties are being explored for simultaneous treatment of MDD and AD.
- QTC-4-MeOBnE is a multi-target ligand affecting BACE, GSK3β, and acetylcholinesterase, with additional neuroinflammation and neurogenesis effects.
Purpose of the Study:
- To investigate the effects of QTC-4-MeOBnE on depressive-like behavior and memory deficits in a transgenic mouse model of AD.
- To assess the compound's impact on AD-related molecular pathways in the cortex and hippocampus.
- To evaluate QTC-4-MeOBnE's potential as a neuroprotective agent for conditions like AD.
Main Methods:
- Administration of QTC-4-MeOBnE (1 mg/kg) for 45 days to 3xTg mice before established pathology.
- Behavioral assessments using the Y-Maze task and forced swimming test to evaluate memory and depressive-like behavior.
- Analysis of molecular changes in the cortex and hippocampus, including amyloid beta (Aβ) production, tau phosphorylation, neuroinflammation, and synaptic integrity.
Main Results:
- QTC-4-MeOBnE treatment significantly prevented memory impairment and reduced depressive-like behavior.
- The compound modulated key AD pathways, including reducing amyloid beta (Aβ) production and hippocampal tau phosphorylation.
- Beneficial effects on neuroinflammation and synaptic integrity were observed, suggesting broad neuroprotective actions.
Conclusions:
- QTC-4-MeOBnE demonstrates moderate efficacy in a transgenic AD model, particularly in preventing cognitive and behavioral deficits.
- The compound's ability to target multiple AD-related pathways highlights its potential as a neuroprotective therapeutic.
- Further research into QTC-4-MeOBnE's neuropsychiatric effects is warranted, especially for its potential in treating conditions like AD.
